Mesoblast: Funding, Investors & Team (Sep 2026)
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes, and kidney disease, orthopedic spine conditions, and cardiovascular disorders.
Mesoblast has raised $165M across 3 funding rounds on record, the most recent an undisclosed round of $50.0M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mesoblast Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Mesoblast Funding Rounds
Mesoblast raised $40.0M in an undisclosed round announced in Apr 2023.
2.7 years later, an undisclosed round of $75.0M was announced in Dec 2025.
6 months later, an undisclosed round of $50.0M was announced in Jun 2026.
Mesoblast Founders and Leadership Team
No contact details are on record for this team yet.
Mesoblast Funding Compared to Other Biotechnology Startups
Mesoblast's latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mesoblast in Biotechnology and Melbourne
Companies Similar to Mesoblast
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to…
Mesoblast Funding FAQs
What does Mesoblast do?
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes, and kidney disease, orthopedic spine conditions, and cardiovascular disorders.
How much funding has Mesoblast raised?
Mesoblast has raised $165M across 3 rounds on record. The most recent is an undisclosed round of $50.0M announced in Jun 2026.
When did Mesoblast last raise funding?
Mesoblast's most recent funding round on record is an undisclosed round of $50.0M, announced in Jun 2026.
Who is the CEO of Mesoblast?
Silviu Itescu is listed as CEO at Mesoblast.
Where is Mesoblast headquartered?
Mesoblast is based in Melbourne, Victoria, Australia.
How many employees does Mesoblast have?
Mesoblast is in the 51-100 employee band.
How does Mesoblast's funding compare to other Biotechnology startups?
Mesoblast's latest round of $50.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Mesoblast Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mesoblast is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.